Literature DB >> 26638998

Aurora-B and HDAC synergistically regulate survival and proliferation of lymphoma cell via AKT, mTOR and Notch pathways.

Chong Wang1, Jing Chen1, Weijie Cao1, Ling Sun1, Hui Sun1, Yanfang Liu2.   

Abstract

Aurora-B is a protein kinase that functions mainly in the attachment of the mitotic spindle to the centromere. Overexpression of Aurora-B causes unequal distribution of genetic information, creating aneuploidy cells, a hallmark of cancer. Histone deacetylases (HDACs) are a class of enzymes that remove acetyl groups from a ε-N-acetyl lysine amino acid on a histone, allowing the histones to wrap the DNA more tightly, thus globally regulating gene transcription. Additionally, these HDACs can also modify non-histone proteins. Inhibition of HDACs is a potent strategy for cancer treatment. Here, we report that inhibition of Aurora-B and HDAC exerts similar tumor suppressive effects in cells. Knockdown of Aurora-B or inhibition of HDAC achieved the same effect on repression of cell proliferation. Furthermore, we found that the tumor suppressive effect of Aurora-B and HDAC inhibition is due to the induction of cell cycle arrest and/or apoptosis. Mechanistically, we demonstrated that Aurora-B and HDAC can cooperatively regulate AKT, mTOR and Notch pathways.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Apoptosis; Aurora-B; Cell cycle; Histone deacetylase; lymphoma

Mesh:

Substances:

Year:  2015        PMID: 26638998     DOI: 10.1016/j.ejphar.2015.11.049

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

1.  Aurora B induces epithelial-mesenchymal transition by stabilizing Snail1 to promote basal-like breast cancer metastasis.

Authors:  Jianchao Zhang; Xinxin Lin; Liufeng Wu; Jia-Jia Huang; Wen-Qi Jiang; Thomas J Kipps; Suping Zhang
Journal:  Oncogene       Date:  2020-01-29       Impact factor: 9.867

2.  Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies.

Authors:  Tanya Siddiqi; Paul Frankel; Jan H Beumer; Brian F Kiesel; Susan Christner; Chris Ruel; Joo Y Song; Robert Chen; Kevin R Kelly; Sikander Ailawadhi; Paul Kaesberg; Leslie Popplewell; Sandrine Puverel; Richard Piekarz; Stephen J Forman; Edward M Newman
Journal:  Leuk Lymphoma       Date:  2019-10-16

3.  Multi-targeted tyrosine kinase inhibitors as third-line regimen in advanced non-small cell lung cancer: a network meta-analysis.

Authors:  Zhonghan Zhang; Yuanyuan Zhao; Feiteng Lu; Xue Hou; Yuxiang Ma; Fan Luo; Kangmei Zeng; Shen Zhao; Yaxiong Zhang; Ting Zhou; Yunpeng Yang; Wenfeng Fang; Yan Huang; Li Zhang; Hongyun Zhao
Journal:  Ann Transl Med       Date:  2019-09

4.  Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors.

Authors:  Yongkun Sun; Wei Niu; Feng Du; Chunxia Du; Shuting Li; Jinwan Wang; Li Li; Fengqing Wang; Yu Hao; Chuan Li; Yihebali Chi
Journal:  J Hematol Oncol       Date:  2016-10-04       Impact factor: 17.388

Review 5.  Aurora kinases: novel therapy targets in cancers.

Authors:  Anqun Tang; Keyu Gao; Laili Chu; Rui Zhang; Jing Yang; Junnian Zheng
Journal:  Oncotarget       Date:  2017-04-04

6.  Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.

Authors:  Leslie A Garrett; Whitfield B Growdon; Bo R Rueda; Rosemary Foster
Journal:  J Ovarian Res       Date:  2016-09-15       Impact factor: 4.234

7.  Aurora-B Promotes Osteosarcoma Cell Growth and Metastasis Through Activation of the NPM1/ERK/NF-κβ/MMPs Axis.

Authors:  Honghai Song; Yang Zhou; Aifen Peng; Jiaming Liu; Xin Wu; Wenzhao Chen; Zhili Liu
Journal:  Cancer Manag Res       Date:  2020-06-23       Impact factor: 3.989

8.  Antitumor effects of anlotinib in thyroid cancer.

Authors:  Xianhui Ruan; Xianle Shi; Qiman Dong; Yang Yu; Xiukun Hou; Xinhao Song; Xi Wei; Lingyi Chen; Ming Gao
Journal:  Endocr Relat Cancer       Date:  2019-01-01       Impact factor: 5.678

9.  Aurora Kinase B Expression, Its Regulation and Therapeutic Targeting in Human Retinoblastoma.

Authors:  Naheed Arfin Borah; Swatishree Sradhanjali; Manas Ranjan Barik; Atimukta Jha; Devjyoti Tripathy; Swathi Kaliki; Suryasnata Rath; Sunil K Raghav; Srinivas Patnaik; Ruchi Mittal; Mamatha M Reddy
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-03-01       Impact factor: 4.799

10.  Anlotinib suppresses metastasis and multidrug resistance via dual blockade of MET/ABCB1 in colorectal carcinoma cells.

Authors:  Lin-Hai Yan; Di Zhang; Si-Si Mo; Hao Yuan; Xian-Wei Mo; Jin-Min Zhao
Journal:  J Cancer       Date:  2021-02-16       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.